# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Marie Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET013-SYN-TD
- Date: 1934-06-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Adaeze Nwosu, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-week review on immunosuppressive therapy, and glare in the right eye. **S**

## History of present illness

Madame Curie returns three weeks after starting horse antithymocyte globulin, cyclosporine, eltrombopag, and acyclovir. She completed the four-day antithymocyte globulin course. She takes cyclosporine twice daily, eltrombopag on an empty stomach away from dairy, and acyclovir twice daily, and has missed no doses. She has had no fever, chills, sore mouth, rash, or joint pain, and no new bleeding beyond occasional bruises. She still tires by midafternoon and is writing at home on shortened days. Glare from the right eye makes small print and night driving difficult, and it is slowing her reading. **S**

| Element | Detail |
|---|---|
| Treatment | Antithymocyte globulin course completed; cyclosporine, eltrombopag, and acyclovir taken as prescribed |
| Infection | No fever, chills, or sore mouth |
| Bleeding | Occasional bruises; no mucosal bleeding |
| Function | Tired by midafternoon; writing at home on shortened days |
| Vision | Right-eye glare slowing her reading; night driving difficult |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue by midafternoon; no fever or chills |
| Hematologic | Positive | Occasional bruises; no mucosal bleeding |
| Eyes | Positive | Glare and blurred reading vision in the right eye; no pain or flashes |
| Skin | Negative | No rash |
| Musculoskeletal | Negative | No joint pain |
| Neurological | Negative | No tremor or headache |

6 systems reviewed. **S**

## Current medications

- Cyclosporine (modified) 100 mg oral capsule, one capsule twice daily, dose adjusted to trough levels by hematology **S**
- Eltrombopag 75 mg oral tablet, two tablets (150 mg) once daily on an empty stomach **S**
- Acyclovir 400 mg oral tablet, one tablet twice daily during immunosuppression **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 90 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 51.5 kg; BMI 20.9 kg/m². All vital signs are synthetic.

Hemoglobin: 8.2 g/dL (low); White blood cell count: 2 10*3/uL (low); Absolute neutrophil count: 0.5 10*3/uL (low); Platelet count: 21 10*3/uL (low); MCV: 102 fL (high); Absolute reticulocyte count: 18 10*3/uL (low); ALT: 28 U/L; Sodium: 138 mmol/L; Potassium: 4.8 mmol/L; Creatinine: 0.96 mg/dL; eGFR: 65 mL/min/1.73 m²; Glucose: 101 mg/dL (high). All results are synthetic.

## Change since baseline

- Hemoglobin: 7.2 g/dL (low) at baseline, 8.2 g/dL (low) at this visit **S**
- White blood cell count: 1.9 10*3/uL (low) at baseline, 2 10*3/uL (low) at this visit **S**
- Absolute neutrophil count: 0.4 10*3/uL (low) at baseline, 0.5 10*3/uL (low) at this visit **S**
- Platelet count: 18 10*3/uL (low) at baseline, 21 10*3/uL (low) at this visit **S**
- MCV: 104 fL (high) at baseline, 102 fL (high) at this visit **S**
- Absolute reticulocyte count: 14 10*3/uL (low) at baseline, 18 10*3/uL (low) at this visit **S**
- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- eGFR: 84 mL/min/1.73 m² at baseline, 65 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 101 mg/dL (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Pale but less tired-looking; alert |
| Mouth | No ulcers, thrush, or gum swelling |
| Skin | A few bruises on the shins; no petechiae or rash |
| Heart | Regular rhythm, pulse 90 |
| Eyes | Right red reflex hazy, with glare on penlight; left red reflex clear |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe aplastic anemia, three weeks into immunosuppressive therapy** (D61.2). No infection or bleeding. Counts have not yet risen, as expected this early: hemoglobin 8.2 g/dL, neutrophils 0.5, platelets 21, reticulocytes 18 thousand per microliter. Creatinine has risen from 0.78 to 0.96 mg/dL (eGFR 65) and potassium is 4.8 on cyclosporine; ALT 28 on eltrombopag. **S**
   - Continue cyclosporine, eltrombopag, and acyclovir.
   - Ask hematology today for a cyclosporine trough with the next counts and a dose review against the creatinine rise.
   - Weekly blood counts with the hematology day unit; transfuse if symptomatic or hemoglobin falls below 7 to 8 g/dL.
2. **Posterior capsule opacification, right eye** (H26.491). Glare and blurred reading in the right eye after earlier cataract surgery are limiting her reading and night driving. **S**
   - Refer to ophthalmology for a comprehensive dilated eye examination and laser capsulotomy if it confirms the cause.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CBC with differential and reticulocyte count | Weekly during the first months of treatment | Completed today | Hemoglobin 8.2 g/dL, white cells 2.0, neutrophils 0.5, platelets 21, reticulocytes 18 thousand per microliter |
| Laboratory | Weekly blood counts between visits | Weekly during the first months of treatment | Deferred | No counts are in this record between the consultation and today, so two weekly counts were missed, a deviation from the protocol. Platelets stayed above 15 and there was no bleeding or fever, so no harm resulted. Corrective action: weekly counts booked with the hematology day unit |
| Laboratory | Creatinine, eGFR, potassium, and ALT on cyclosporine and eltrombopag | Every two weeks during the first months of treatment | Completed today | First check, three weeks after starting, a week later than the two-week schedule. Creatinine 0.96 mg/dL (up from 0.78), eGFR 65, potassium 4.8, ALT 28, sodium 138; glucose 101 mg/dL, slightly high |
| Laboratory | Cyclosporine trough level | Regularly from the first weeks of treatment, to guide the dose | Deferred | No trough level is in this record since cyclosporine started, a deviation from the protocol. The creatinine rise may reflect cyclosporine effect. Corrective action: trough requested from hematology with the next counts |
| Laboratory | Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV) | At diagnosis, before immunosuppression | Deferred | Still not in this record; not sent with today's blood, a second miss. ALT is normal, with no sign of hepatitis. Corrective action: results requested from hematology |
| Examination | Blood pressure and weight on cyclosporine | Every visit | Completed today | 124/76 mmHg, up from 116/70 before cyclosporine; weight 51.5 kg |
| Medication safety | Antiviral prophylaxis during immunosuppression | Throughout immunosuppression | Completed today | Taking acyclovir twice daily |
| Medication safety | Antibacterial and antifungal prophylaxis while severely neutropenic | While neutrophils are below 0.5 thousand per microliter, by local policy | Deferred | Still not prescribed; neutrophils 0.5, at the threshold, with no infection. Hematology to confirm under local policy |
| Medication safety | Eltrombopag administration | Every visit | Completed today | Taken on an empty stomach, away from dairy and antacids |
| Self-management | Same-day assessment for a temperature of 38 °C or higher; bleeding precautions; no aspirin or NSAIDs | Every visit | Completed today | No fever; plan reviewed |
| Survey | Symptom assessment (fatigue, breathlessness, exercise tolerance) | Every visit during active treatment | Completed today | Tired by midafternoon; breathless after one flight of stairs |
| Survey | Functional vision assessment (reading, driving, work) | When symptoms limit daily tasks | Completed today | Glare limits small print, reading, and night driving |
| Referral | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older, and with new functional impairment | Referred | Ophthalmology appointment next week |
| Survey | Response assessment (blood counts off transfusion) | At three and six months | Due | Formal response is judged at three months |
| Survey | Depression screen (PHQ-2) | Periodically during serious illness | Due | Score 1 at intake; repeat at the next visit |

## Goal progress

- Hematology evaluation with bone marrow biopsy within one week of the pancytopenia result. Outcome by 1934-05-18: Seen and biopsied seven days after the first visit. **S**
- No serious infection or bleeding during the first months of treatment. In progress; target 1934-06-29. **S**
- Early rise in neutrophil and platelet counts by the six-week visit. In progress; target 1934-06-29. **S**
- Read standard print comfortably with the right eye after capsulotomy. In progress; target 1934-06-29. **S**

## Guideline basis

- Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (2024), British Society for Haematology (British Journal of Haematology)
- Cataract in the Adult Eye Preferred Practice Pattern (2021), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, anemia and cataract monographs (2026), Aether Forge

## Follow-up

- Weekly blood counts. Ophthalmology next week. Primary care review in three weeks with blood counts, kidney function, potassium, and ALT. **S**
- Next scheduled visit 1934-06-29: primary care follow-up six weeks into immunosuppressive therapy, after laser capsulotomy of the right eye. **S**
